Incannex Healthcare Inc.
For the period ended Dec 31, 2025. Filed Feb 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Dec 31, 2025 · Filed Feb 13, 2026
IXHL$2.01-8.2%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
| For the six months ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Cash flows from operating activities: | ||
| Net loss | $(12,928) | $(11,313) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation and amortization | 125 | 190 |
| Unrealized loss on foreign currency remeasurement | 37 | 273 |
| Non-cash expense of ELOC commitment | - | 1,095 |
| Stock-based compensation expense | 4,905 | 894 |
| Change in fair value of warrant liabilities | - | 103 |
| Change in fair value of convertible rights | - | 179 |
| Non-cash interest expense | - | 176 |
| Change in operating assets and liabilities: | ||
| Prepaid expenses and other current assets | 350 | 146 |
| R&D tax incentive | (922) | 2,627 |
| Securities pledged | - | (1,383) |
| Trade and other payables | (5,352) | (859) |
| Net cash used in operating activities | (13,785) | (7,872) |
| Cash flows from investing activities: | ||
| Purchase of property, plant and equipment | (6) | (8) |
| Investment of joint venture | (40) | - |
| Net cash used in investing activities | (46) | (8) |
| Cash flows from financing activities: | ||
| Proceeds received from facility agreement | - | 4,282 |
| Repayment of facility agreement | - | (2,898) |
| Proceeds from share issuance | 71,662 | - |
| Share issuance costs | (2,379) | - |
| Proceeds from issuance of convertible debt | - | 2,779 |
| Debt issuance costs | - | (113) |
| Share repurchase | (1,179) | - |
| Net cash provided by financing activities | 68,104 | 4,050 |
| Effect of exchange rate changes on cash and cash equivalents | (119) | 70 |
| Net increase/(decrease) in cash, cash equivalents, and restricted cash | 54,272 | (3,830) |
| Cash and cash equivalents, and restricted cash at beginning of period | 15,039 | 5,858 |
| Cash and cash equivalents, and restricted cash at end of period | $69,193 | $2,098 |
| Non-cash investing and financing activities | ||
| Issuance of ELOC warrants at initial fair value | - | 1,284 |
| Issuance of convertible note warrants at initial fair value | - | 543 |
| Issuance of convertible rights at initial fair value | - | 449 |
| Total | - | 2,276 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.